Home » Stocks » Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)

Stock Price: $79.77 USD 2.15 (2.77%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.76B
Revenue (ttm) 10.85M
Net Income (ttm) -321.42M
Shares Out 59.69M
EPS (ttm) -11.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $79.77
Previous Close $77.62
Change ($) 2.15
Change (%) 2.77%
Day's Open 77.44
Day's Range 77.10 - 79.94
Day's Volume 473,354
52-Week Range 26.56 - 79.94

More Stats

Market Cap 4.76B
Enterprise Value 4.50B
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 59.69M
Float 51.74M
EPS (basic) -6.30
EPS (diluted) -11.10
FCF / Share -8.92
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.66M
Short Ratio 19.02
Short % of Float 18.68%
Beta 1.19
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 438.86
PB Ratio 31.82
Revenue 10.85M
Operating Income -282.41M
Net Income -321.42M
Free Cash Flow -523.93M
Net Cash 261.06M
Net Cash / Share 4.37
Gross Margin -2,665.70%
Operating Margin -2,603.08%
Profit Margin -2,962.70%
FCF Margin -4,829.27%
ROA -73.35%
ROE -805.56%
ROIC 770.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$87.70*
(9.94% upside)
Low
63.0
Current: $79.77
High
109.0
Target: 87.70
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-225-108-108-60.64-9.70
Net Income-241-127-127-63.53-10.07
Shares Outstanding39.1927.8527.8512.6111.01
Earnings Per Share-6.15-5.00-5.00-5.05-0.91
Operating Cash Flow-377-197-94.82-29.50-5.63
Capital Expenditures-3.78-4.17-0.54-0.03-
Free Cash Flow-381-201-95.36-29.53-5.63
Cash & Equivalents31726413123.571.46
Total Debt---4.81-
Net Cash / Debt31726413118.751.46
Assets34429014727.021.89
Liabilities35213914.9228.780.81
Book Value-7.42151132-45.031.14
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biohaven Pharmaceutical Holding Co. Ltd.
Country United States
Employees 647
CEO Vlad Coric

Stock Information

Ticker Symbol BHVN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: BHVN
IPO Date May 4, 2017

Description

Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.